Navigation Links
SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility
Date:4/30/2008

Another Top Flight Sport's Training Institute joins the SURGEX(TM) Team

BASKING RIDGE, N.J., April 30 /PRNewswire/ -- Millennium Biotechnologies Inc., wholly-owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), announced today that SURGEX(TM) has become the official sports nutrition drink of The Edge Training Facility, http://www.edgebasketball.com, Florida's premier basketball training facility for NBA stars and young emerging basketball talent. Dee Brown, former Boston Celtic, Orlando Magic Toronto Raptor player, winner of the "no look" 1991 Slum Dunk Contest and WNBA Head Coach, is the CEO and head instructor at The Edge Training Facility. At the Edge Training Facility he and his experienced instructors work with current NBA stars and young basketball players to improve their strength and basketball skills.

Dee Brown and The Edge Training Facility are proud to have SURGEX(TM) as the official sports nutrition drink for their athletes. "Edge prides itself on creating and utilizing only cutting edge techniques and equipment to advance their client's skills. The strength and recovery benefits of SURGEX(TM) are key additions to our overall training protocols," says Dee Brown.

Dee Brown can be heard along with veteran broadcaster Ian Eagle and ex NBA star Rick Mahorn breaking down this year's NBA playoffs on Sirius Satellite Radio's weekday show "Full Court Press" from 12:00-3:00 EDT on channel 127.

About SURGEX(TM):

SURGEX(TM) (http://www.surgexsports.com) was created from Millennium's extensive experience providing advanced nutritional formulas to some of the most prestigious medical institutions throughout the United States. The proprietary SURGEX(TM) formula intends to meet the growing demand of professional, amateur, and Olympic athletes as well as their coaches looking for nutritional support in a marketplace dominated by products with no clinical proof of benefit, unsubstantiated claims, excess protein, stimulants, and banned substances.

In two double blind placebo controlled clinical trials conducted at the Rutgers University Human Performance Lab SURGEX(TM) significantly outperformed leading competitive products by assisting in reducing the damaging effects of exercise. SURGEX(TM) proved to be a superior product by improving peak power outputs, lowering oxidative stress/inflammatory markers, reducing fatigue (poor energy recovery) and the breakdown of muscle (post exercise wasting), as well as reducing free radical production (oxidative stress). The formula meets NCAA guidelines for use by collegiate athletes and is certified by The Banned Substances Control Group (BSCG) to contain no banned substances.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC"). These statements have not been evaluated by the Food and Drug Administration. Resurgex(R), Resurgex Plus(R), Resurgex Select(R) and SURGEX(TM) are not intended to diagnose, treat, cure, or prevent and disease.


'/>"/>
SOURCE Millennium Biotechnologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
2. Pro Football Prospects Training at TEST Sports Clubs(TM) Use SURGEX(TM) as Part of Their Pre-Combine Training Regime
3. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
4. Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors
5. REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
6. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
7. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
8. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
9. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
10. Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008
11. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on ... that it will present at the 18 th ... 8, 2016 at 10:00 a.m. EST in New ... DelMar,s president and CEO, will provide an update on the ...
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/4/2016)... Strasbourg, France , to the US ... Strasbourg, France , to the US company Advanced Bioscience ... announce that it acted as an advisor to Transgene on ... Strasbourg, France , to the US company Advanced Bioscience ... Transgene (Euronext: TNG), a member of Institut Mérieux, is ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, Inc. ... on developing aerosolized KL4 surfactant therapies for respiratory ... has approved an inducement award as a component ... its newly appointed President and Chief Executive Officer.  ... Committee on February 1, 2016 and granted as ...
Breaking Biology Technology:
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 /PRNewswire/ ... sensor-based diagnostic products, today announced the closing of a $9 ... investors.  Proceeds from the financing will be used to accelerate ... device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has been ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
(Date:1/6/2016)... Jan. 6, 2016 Based on its ... & Sullivan recognizes MorphoTrak, LLC, a U.S. subsidiary ... Frost & Sullivan Company of the Year Award. ... technology, Morpho Wave™ , has consolidated the company,s ... biometrics market. Morpho Wave is a highly ...
Breaking Biology News(10 mins):